1 October 2015 - Ceritinib (Zykadia) has been available since May 2015 for the treatment of adult patients with non small-cell lung cancer after the use of crizotinib.

The Institute for Quality and Efficiency in Health Care (IQWiG) has checked in a dossier evaluation whether ceritinib when compared with an appropriate comparator therapy offers an additional benefit. However, such additional benefits cannot be determined from the dossier, because it does not contain appropriate data for the evaluation.

The Federal Joint Committee (G-BA) has distinguished two target patient populations for ceritinib; in patients for which chemotherapy with docetaxel or pemetrexed is eligible, ceritinib should be compared with one of these two agents. 

In patients where the use of chemotherapy is not an option, the G-BA has determined best supportive care (BSC) to be an appropriate comparator therapy.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/ceritinib-bei-fortgeschrittenem-lungenkrebs-kein-anhaltspunkt-fur-zusatznutzen.6914.html?&et_cid=4&et_lid=%25208